. 1999 Jun;69(4):274-6.

Short-term effects of fluvastatin, a hydroxylmethylglutaryl-coenzyme A reductase inhibitor, on coagulation and the fibrinolytic system in patients with hypercholesterolemia

M Saito et al. Int J Hematol. 1999 Jun.

. 1999 Jun;69(4):274-6.

No abstract available

Similar articles

The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.
Lin TH, Huang CH, Voon WC, Yen HW, Lai HM, Liang HY, Lu YH, Lee KT, Lee CS, Lai WT, Sheu SH. Lin TH, et al. Kaohsiung J Med Sci. 2000 Dec;16(12):600-6. Kaohsiung J Med Sci. 2000. PMID: 11392099
Another view of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the fibrinolytic system.
Emeis JJ, Cohen LH. Emeis JJ, et al. Am J Cardiol. 1997 Oct 1;80(7):977-8. Am J Cardiol. 1997. PMID: 9382029 No abstract available.
Fluvastatin and fluvastatin extended release: a clinical and safety profile.
Asberg A, Holdaas H. Asberg A, et al. Expert Rev Cardiovasc Ther. 2004 Sep;2(5):641-52. doi: 10.1586/14779072.2.5.641. Expert Rev Cardiovasc Ther. 2004. PMID: 15350166 Review.
Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, Santoli E, Norbiato G. Bevilacqua M, et al. Am J Cardiol. 1997 Jan 1;79(1):84-7. doi: 10.1016/s0002-9149(96)00684-4. Am J Cardiol. 1997. PMID: 9024745 Clinical Trial.
[Fluvastatin].
Teramoto T. Teramoto T. Nihon Rinsho. 2001 Mar;59 Suppl 3:587-91. Nihon Rinsho. 2001. PMID: 11347136 Review. Japanese. No abstract available.